# Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

> **NCT04006041** · PHASE2 · UNKNOWN · sponsor: **Jianhua Fu** · enrollment: 44 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Resectable Esophageal Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Paclitaxel/cisplatin
- **RADIATION:** Intensity-modulated radiotherapy
- **PROCEDURE:** Esophagectomy

## Key facts

- **NCT ID:** NCT04006041
- **Lead sponsor:** Jianhua Fu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-25
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2019-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006041, "Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04006041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*